VIAP 财务： VIA Pharmaceuticals Inc AI 分析

主页

股票

VIAP

财务数据

VIAP 财务

VIA Pharmaceuticals Inc

收盘价：Mar 24, 16:00:00 GMT-4

盘后：Mar 24, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

VIAP 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2010	12/31/2009	12/31/2008	12/31/2007	12/31/2006
营收	0	0	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	--
营收成本	--	--	--	--	--	--
毛利润	--	--	--	--	--	--
销售、一般及管理费用	4	4	7	8	7	2
研发	1	1	6	11	10	5
营业费用	5	5	13	20	18	8
其他非经营性收入 (费用)	0	0	0	0	0	0
税前利润	-9	-9	-20	-20	-21	-8
所得税费用	0	0	0	0	0	0
净利润	-9	-9	-20	-20	-21	-8
净利润增长	-55%	-55%	0%	-5%	163%	-57.99%
稀释后流通股数	20.51	20.39	19.93	19.6	9.72	0.43
股份同比变动 (YoY)	2%	2%	2%	102%	2,133%	-97%
每股收益 (摊薄)	-0.47	-0.47	-1.05	-1.03	-2.24	-19.8
每股收益增长率	-55%	-55%	2%	-54%	-89%	1,601%
自由现金流	-6	-6	-11	-19	-19	-8
每股自由现金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
营业利润率	0%	0%	0%	0%	0%	0%
净利率	0%	0%	0%	0%	0%	0%
自由现金流利润率	0%	0%	0%	0%	0%	0%
EBITDA	-5	-5	-13	-20	-18	-8
EBITDA 利润率	0%	0%	0%	0%	0%	0%
EBITDA 中的折旧与摊销	0	0	0	0	0	0
EBIT	-5	-5	-13	-20	-18	-8
EBIT 利润率	0%	0%	0%	0%	0%	0%
有效税率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

VIA Pharmaceuticals Inc 的关键财务报表是什么？



根据最新的财务报表（Form-10K），VIA Pharmaceuticals Inc 的总资产为 $0，净损失为 $-9

VIAP 的关键财务比率是什么？



VIA Pharmaceuticals Inc 的流动比率是 0，净利 margin 为 0，每股销售为 $0。

VIA Pharmaceuticals Inc 的收入按细分市场或地理位置如何划分？



VIA Pharmaceuticals Inc 最大收入来源是 Other，在最近的收益报告中收入为 2,369,000,000。就地区而言， Italy 是 VIA Pharmaceuticals Inc 的主要市场，收入为 30,994,000,000。

VIA Pharmaceuticals Inc 是否盈利？



不，根据最新的财务报表，VIA Pharmaceuticals Inc 的净损失为 $-9

VIA Pharmaceuticals Inc 有负债吗？



是的，VIA Pharmaceuticals Inc 的负债为 18

VIA Pharmaceuticals Inc 的流通股有多少？



VIA Pharmaceuticals Inc 的总流通股为 20.55

关键数据

前收盘价

$0.0005

开盘价

当日区间

$0 - $0.0005

52周范围

$0 - $0.0005

交易量

700

平均成交量

股息收益率

每股收益（TTM）

-0.47

市值

$10.2K

什么是 VIAP？

VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.

功能特性

资源